Search Results 1-10 of 3544 for ���������������������������������������������:PC90���

  2. A Study to Evaluate Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer - Mayo Clinic

    Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with ...

  3. Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma - Mayo Clinic

    About this study. Patients with previously untreated low tumor burden indolent Non-Hodgkin's Lymphoma (NHL) will receive either rituximab or GA101 weekly ...

  4. Videos - Bioinformatics Core - Mayo Clinic Research

    Videos highlight how the Bioinformatics Core at Mayo Clinic supports research in the Mayo Clinic Cancer Center and the Center for Individualized Medicine.

  5. A Study of Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M) - Mayo Clinic

    The purpose of this study is to evaluate the investigational drug PledOx in the prevention of chronic chemotherapy induced peripheral neuropathy (CIPN) induced ...

  6. Tailored Antiplatelet Therapy Following PCI - Mayo Clinic

    Clopidogrel is an anti-platelet medication approved by the U.S. Federal Drug Administration (FDA) for use in patients who undergo Percutaneous Coronary ...

  7. Phase I Study of LB-100 With Docetaxel in Solid Tumors - Mayo Clinic

    LB-100 is a small molecule that in laboratory and animal studies has shown activity when used by itself or together with drugs approved to treat some types of ...

  8. A Study of Carotid MRI/MRA to Evaluate the Amount of Plaque in the Arteries of Patients Taking Cholesterol Lowering Medication - Mayo Clinic

    About this study. The purpose of this study is to assess if it is possible to use a carotid MRI/MRA to see if cholesterol lowering medication is causing a ...

  9. A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  10. A Study to Provide Access to CTL019 Out of Specification Managed Access Program (MAP) for ALL or DLBCL Patients - Mayo Clinic

    The purpose of this study is to provide access to CTL019 through Managed Access Program (MAP) for acute lymphoblastic leukemia (ALL) or diffuse large b-cell ...